:: Library Catalog

Copertina

Salvato in:

Dettagli Bibliografici
Autori principali:	Yu‐Sheng Lin, Ying‐Cheng Lin, Teng‐Yu Lee
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	https://onlinelibrary.wiley.com/doi/10.1111/apt.70643
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
di: Subin Heo, et al.
Pubblicazione: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
di: Jiwon Yang, et al.
Pubblicazione: (2025)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
di: Kuo‐Cheng Wu, et al.
Pubblicazione: (2024)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
di: Elisa Pinto, et al.
Pubblicazione: (2026)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
di: Gamal Shiha, et al.
Pubblicazione: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
di: Daniel Q. Huang, et al.
Pubblicazione: (2026)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
di: Shuaibing Ying, et al.
Pubblicazione: (2026)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
di: Dong Hyun Kim, et al.
Pubblicazione: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
di: Zhejin Shi, et al.
Pubblicazione: (2026)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
di: Jia‐Ling Wu, et al.
Pubblicazione: (2025)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
di: Jonggi Choi
Pubblicazione: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
di: Mohamed El‐Kassas, et al.
Pubblicazione: (2025)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease. Authors' Reply
di: Walter W. Chan, et al.
Pubblicazione: (2026)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
di: Sifu Yang
Pubblicazione: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
di: Isabel Carbery, et al.
Pubblicazione: (2024)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
di: J. M. Schattenberg, et al.
Pubblicazione: (2026)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
di: Shintaro Akiyama, et al.
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
di: Irene Spinelli, et al.
Pubblicazione: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
di: Lesley A. Patmore, et al.
Pubblicazione: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply
di: Gamal Shiha, et al.
Pubblicazione: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
di: Eunice Yewon Lee, et al.
Pubblicazione: (2024)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
di: Yuanyan Sun, et al.
Pubblicazione: (2026)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
di: Ning Yu, et al.
Pubblicazione: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
di: Tanat Saeoui, et al.
Pubblicazione: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
di: Nina Dominik, et al.
Pubblicazione: (2024)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
di: Nathan Grellier, et al.
Pubblicazione: (2025)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
di: Teresa Seum, et al.
Pubblicazione: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
di: Anupam Kumar Singh, et al.
Pubblicazione: (2026)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study
di: Ahmed Helmy
Pubblicazione: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
di: Lukas Burghart, et al.
Pubblicazione: (2026)